BioSpace News Archive

Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, announced the launch of its new pipeline company, Telos Biotech.

Edesa Biotech, Inc. today announced that the company’s board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023.

Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or “Company”) today announced results from a third round of consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks and under the tongue.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for aflibercept 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR), solely due to an ongoing review of inspection findings at a third-party filler.

Ascendia Pharmaceuticals CEO Jim Huang, Ph.D. announces Ascendia’s patented EmulSol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval from the Food & Drug Administration (FDA).

CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, reports that after nearly a year of research, the UCLA team is ready to begin integrating their combined work into a complete vaccine construct for next phase testing and optimization.

Koning Corporation, a global leader in breast computed tomography technology, is thrilled to announce the launch of its breakthrough Artificial Intelligence software, designed to enhance image quality significantly.

SIGA Technologies, Inc. announced that SIGA CEO Phil Gomez, PhD, will present an overview of the role of therapeutics in global planning and response to potential outbreaks of smallpox and other orthopox viruses during the upcoming NATO Chemical, Biological, Radiological & Nuclear Medical Symposium in Oak Ridge, Tennessee.

Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that a new therapy to treat the most common type of non-Hodgkin lymphoma in adults – diffuse large B-cell lymphoma – is now approved for use in Australia.

Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to lead clinical candidate VCN-01, Theriva’s systemic, selective, stroma-degrading oncolytic adenovirus for the treatment of pancreatic cancer.